Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema

Trial Profile

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Eczema
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 03 Dec 2018 According to a Leo Pharma media release, the company announced that they have initiated the trials and have enrolled the first patients in two new phase 2b studies to investigate delgocitinib as a monotherapy for adults with with mild-to-severe atopic dermatitis (AD) as well as mild-to-severe chronic hand eczema (CHE).
    • 03 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 28 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top